anoth solid guidanc rais
sale y/i solidli beat our/street
better expect us perform led on-going roll-out
rais sale guidanc gross margin
line sg leverag off-set slightli higher lead
better oper margin vs competit remain high
particularli libr pend overal market acceler continu
insulin-intens penetr start becom meaning doubl
market opportun us near-term opportun focu includ
broaden pharmaci channel reach intern expans japan particular
pump partnership latter time track limit launch
see product potenti share-gain market-expand
us/ou sale exceeded/miss forecast
intern manag note typic lumpi europ still
predominantli sell third-parti distributor
ahead estim gm impact infrastructur invest
expect slightli higher vs estim sg lower
vs
note revenue/pati headwind expect payer negoti
access continu expans medicare/ busi
new-pati growth initi offset lower medicar
reimburs impact sale start lower cost fewer sensors/no
bgm off-set margin az facil ramp launch low-cost
transmitt gm driver exit
guidanc manag rais sale guidanc impli
y/i growth gm guidanc reiter non-
oper margin rais impli y/i margin
expans adjust ebitda margin rais guidanc
build revenue-per-pati headwind
pipelin track on-going small trial system featur get refin
recal significantli downsiz one-piec dispos system
extend wear lower-cost design provid flexibl beyond ad
benefit provid current focused-on market
design also open big new market start non-intens
estim sale estim increas
us/ou ep rise higher sale
oper leverag forecast sale
ep ou expans potenti upsid driver higher
estim pt rise
year price histori
medic devic
compani focus design
develop continu glucos
monitor system diabet patient
lead product cgm
analyst certif import disclosur see disclosur
cgm penetr type diabet reach
next year
us growth remain solid market channel
expans well medicar contribut off-set lower revenue-p
modest acceler intens type patient non-medicar
greater volum acceler pharmaci access
type contribut sale beyond current modest current
under-penetrated patient popul robust pipelin
forecast solid sale growth next sever year
partnership system new market opportun includ
launch hybrid closed-loop system pump partner
competitor launch lead greater market share loss
price target driven blend discount cash flow assum weight averag cost capit
termin growth rate base estim ebitda price target impli ev/sal multipl
risk includ competit slowdown revenu due macroeconom pressur clinic trial fda risk
